Document is current
Any future updates will be listed below
-
Authors
Modica, Chiara
Basilico, Cristina https://orcid.org/0000-0002-8722-5485
Chiriaco, Cristina
Borrelli, Nicla
Comoglio, Paolo M.
Vigna, Elisa
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (21052, 21052)
Fondazione Piemontese per la Ricerca sul Cancro (5x1000 2014)
Ministero della Salute (Ricerca Corrente 2019)
Metis Precision Medicine B-Corp (Resource 2020)
- License Information
-
More Information
Article History
Received: 27 August 2020
Accepted: 22 December 2020
First Online: 14 January 2021
Ethics approval and consent to participate
: All in vivo experiments were performed according to protocols approved by the Ethical Committee for animal experimentation of the Fondazione Piemontese per la Ricerca sul Cancro and by the Italian Ministry of Health. The Cancer of Unknown Primary human sample was collected through the Agnostos program, a clinical and translational platform developed at the Candiolo Cancer Institute including a prospective, randomized phase-II clinical trial (NCT02607202), and the Agnostos Profiling study approved by the Institute Ethical Committee. Informed consensus was obtained from patient, and the experiments were conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
: All authors who have contributed to the study agree to publish it.
: PMC and EV are co-founders of Metis Precision Medicine B-Corp (Italy). CB, PMC and EV are authors of the patent application N. WO2019180658A1 (“New combination of therapeutic agents for the treatment of a tumor and /or metastases”). The company did not interfere in the design of the study, analysis of data and decision to publish. The other authors declare no potential conflict of interest.
